Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions
Open Access
- 14 December 2020
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (24) , 9511
Abstract
Pituitary Gonadotropin-Releasing Hormone receptors (GnRH-R) mediate the activity of the hypothalamic decapeptide GnRH, thus playing a key role in the regulation of the reproductive axis. Early-stage prostate cancer (PCa) is dependent on serum androgen levels, and androgen-deprivation therapy (ADT), based on GnRH agonists and antagonists, represents the standard therapeutic approach for PCa patients. Unfortunately, the tumor often progresses towards the more aggressive castration-resistant prostate cancer (CRPC) stage. GnRH receptors are also expressed in CRPC tissues, where their binding to both GnRH agonists and antagonists is associated with significant antiproliferative/proapoptotic, antimetastatic and antiangiogenic effects, mediated by the Gαi/cAMP signaling cascade. GnRH agonists and antagonists are now considered as an effective therapeutic strategy for CRPC patients with many clinical trials demonstrating that the combined use of these drugs with standard therapies (i.e., docetaxel, enzalutamide, abiraterone) significantly improves disease-free survival. In this context, GnRH-based bioconjugates (cytotoxic drugs covalently linked to a GnRH-based decapeptide) have been recently developed. The rationale of this treatment is that the GnRH peptide selectively binds to its receptors, delivering the cytotoxic drug to CRPC cells while sparing nontumor cells. Some of these compounds have already entered clinical trials.Keywords
Funding Information
- Department of Pharmacological and Biomolecular Sciences, Univeristà degli Studi di Milano (MIUR Progetto di Eccellenza)
- Associazione Italiana per la Ricerca sul Cancro (AIRC fellowship (F.F.))
This publication has 207 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexateEuropean Journal of Medicinal Chemistry, 2012
- Anthracycline-GnRH derivative bioconjugates with different linkages: Synthesis, in vitro drug release and cytostatic effectJournal of Controlled Release, 2011
- An update on the use of gonadotropin-releasing hormone antagonists in prostate cancerTherapeutic Advances in Urology, 2011
- Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein KinasesMicrobiology and Molecular Biology Reviews, 2011
- Efficacy of a Second Line Luteinizing Hormone-Releasing Hormone Agonist After Advanced Prostate Cancer Biochemical RecurrenceJournal of Urology, 2011
- Diversity of actions of GnRHs mediated by ligand-induced selective signalingFrontiers in Neuroendocrinology, 2008
- Expression of GnRH type II is regulated by the androgen receptor in prostate cancerEndocrine-Related Cancer, 2007
- A Gonadotropin-Releasing Hormone (GnRH) Receptor Specific for GnRH II in PrimatesBiochemical and Biophysical Research Communications, 2001
- Isolation and properties of the FSH and LH-releasing hormoneBiochemical and Biophysical Research Communications, 1971